NO20024587L - Forbindelser med (celle-) mÕlsökende evne - Google Patents

Forbindelser med (celle-) mÕlsökende evne

Info

Publication number
NO20024587L
NO20024587L NO20024587A NO20024587A NO20024587L NO 20024587 L NO20024587 L NO 20024587L NO 20024587 A NO20024587 A NO 20024587A NO 20024587 A NO20024587 A NO 20024587A NO 20024587 L NO20024587 L NO 20024587L
Authority
NO
Norway
Prior art keywords
caspase
compound
cytotoxic
constitutively active
connections
Prior art date
Application number
NO20024587A
Other languages
English (en)
Norwegian (no)
Other versions
NO20024587D0 (no
Inventor
Agamemnon Antoniou Epenetos
Original Assignee
Antisoma Res Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Antisoma Res Ltd filed Critical Antisoma Res Ltd
Publication of NO20024587D0 publication Critical patent/NO20024587D0/no
Publication of NO20024587L publication Critical patent/NO20024587L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6472—Cysteine endopeptidases (3.4.22)
    • C12N9/6475—Interleukin 1-beta convertase-like enzymes (3.4.22.10; 3.4.22.36; 3.4.22.63)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/22—Cysteine endopeptidases (3.4.22)
    • C12Y304/22056—Caspase-3 (3.4.22.56)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/22—Cysteine endopeptidases (3.4.22)
    • C12Y304/22059—Caspase-6 (3.4.22.59)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cephalosporin Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
NO20024587A 2000-03-28 2002-09-25 Forbindelser med (celle-) mÕlsökende evne NO20024587L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0007343A GB2360771A (en) 2000-03-28 2000-03-28 Compounds for targeting
PCT/GB2001/001354 WO2001072336A1 (en) 2000-03-28 2001-03-28 Compounds for targeting

Publications (2)

Publication Number Publication Date
NO20024587D0 NO20024587D0 (no) 2002-09-25
NO20024587L true NO20024587L (no) 2002-11-25

Family

ID=9888460

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20024587A NO20024587L (no) 2000-03-28 2002-09-25 Forbindelser med (celle-) mÕlsökende evne

Country Status (21)

Country Link
EP (1) EP1267940B1 (de)
JP (1) JP2003528156A (de)
KR (1) KR20030022782A (de)
CN (1) CN1420789A (de)
AT (1) ATE240122T1 (de)
AU (1) AU4850101A (de)
BR (1) BR0109570A (de)
CA (1) CA2402453A1 (de)
DE (1) DE60100274T2 (de)
DK (1) DK1267940T3 (de)
ES (1) ES2202287T3 (de)
GB (2) GB2360771A (de)
IL (1) IL151675A0 (de)
MX (1) MXPA02009376A (de)
NO (1) NO20024587L (de)
NZ (1) NZ521289A (de)
PL (1) PL358482A1 (de)
PT (1) PT1267940E (de)
RU (1) RU2002128746A (de)
WO (1) WO2001072336A1 (de)
ZA (1) ZA200207157B (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU783679B2 (en) * 2000-02-24 2005-11-24 Genentech Inc. Caspase activated prodrugs therapy
CA2475247C (en) * 2002-02-07 2015-08-04 Massachusetts Institute Of Technology Anti-pathogen treatments
EP2571992B1 (de) * 2010-05-21 2018-04-25 Merrimack Pharmaceuticals, Inc. Bispezifische fusionsproteine
JP7592621B2 (ja) * 2019-04-02 2024-12-02 イミュネチューン・ベー・フェー 免疫刺激組成物及びその使用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9019553D0 (en) * 1990-09-07 1990-10-24 Unilever Plc Specific binding agents
DE69133036T2 (de) * 1990-11-09 2003-02-06 Stephen D. Gillies Cytokine immunokonjugate
GB9120467D0 (en) * 1991-09-26 1991-11-06 Celltech Ltd Anti-hmfg antibodies and process for their production
WO1994011508A2 (en) * 1992-11-13 1994-05-26 Cancer Research Fund Of Contra Costa Polypeptides with specificity for neoplasias, kit, and diagnostic, vaccination, and therapeutic methods
GB2289679B (en) * 1993-01-15 1997-02-05 Imp Cancer Res Tech Compounds comprising a target cell-specific portion and a portion which has DNA endonucleolytic activity, and uses thereof
US5587459A (en) * 1994-08-19 1996-12-24 Regents Of The University Of Minnesota Immunoconjugates comprising tyrosine kinase inhibitors
US6428788B1 (en) * 1995-03-15 2002-08-06 Penn State University Compositions and methods for specifically targeting tumors
WO1999029721A1 (en) * 1997-12-10 1999-06-17 Washington University Anti-pathogen system and methods of use thereof
US6379950B1 (en) * 1998-01-09 2002-04-30 Thomas Jefferson University Recombinant, active caspases and uses thereof
US6645490B2 (en) * 1998-03-02 2003-11-11 Yissum Research Development Company Of The Hebrew University Of Jerusalem Chimeric proteins with cell-targeting specificity and apoptosis-inducing activities

Also Published As

Publication number Publication date
GB2360771A (en) 2001-10-03
CA2402453A1 (en) 2001-10-04
MXPA02009376A (es) 2004-05-14
DE60100274T2 (de) 2004-04-01
GB0107725D0 (en) 2001-05-16
GB2360772A (en) 2001-10-03
IL151675A0 (en) 2003-04-10
ZA200207157B (en) 2003-12-05
BR0109570A (pt) 2003-01-28
DE60100274D1 (de) 2003-06-18
KR20030022782A (ko) 2003-03-17
NZ521289A (en) 2004-04-30
EP1267940B1 (de) 2003-05-14
ATE240122T1 (de) 2003-05-15
PT1267940E (pt) 2003-09-30
ES2202287T3 (es) 2004-04-01
NO20024587D0 (no) 2002-09-25
EP1267940A1 (de) 2003-01-02
DK1267940T3 (da) 2003-09-08
GB0007343D0 (en) 2000-05-17
CN1420789A (zh) 2003-05-28
PL358482A1 (pl) 2004-08-09
AU4850101A (en) 2001-10-08
GB2360772B (en) 2002-05-22
RU2002128746A (ru) 2004-03-27
JP2003528156A (ja) 2003-09-24
WO2001072336A1 (en) 2001-10-04

Similar Documents

Publication Publication Date Title
WO2001072962A3 (en) Novel prostate-specific or testis-specific nucleic acid molecules, polypeptides, and diagnostic and therapeutic methods
NO20014415L (no) Medisinske preparater til behandling av <alfa>-galaktosidase- A-defisiens
BR0308090A (pt) conjugados de agentes citotóxicos ou terapêuticos e peptìdios biologicamente ativos
WO2003096990A3 (en) Protein cages for the delivery of medical imaging and therapy
EP1414471A4 (de) Therapeutische mittel mit pro-apoptotischen proteinen
IL115517A0 (en) Biologically active proteins
PT1641483E (pt) Proteínas de fusão
WO2005062977A3 (en) Prostate cancer specific internalizing human antibodies
DK1282443T3 (da) Gendetektionsassay til at forbedre sandsynligheden for et effektivt respons på en ErbB-antagonist cancerterapi
WO2001087227A3 (en) Drug containing polymeric micelles
ATE355288T1 (de) Verbindungen und therapeutische methoden
NO20055838L (no) Aktive varianter av IL-18 bindende protein og medisinske anvendelser derav
NO20055209D0 (no) Peptabody for cancerbehandling
ATE235551T1 (de) Ligand (tie ligand-4) vom tie-2 rezeptor und dessen verwendungen
NO20024587D0 (no) Forbindelser med (celle-) målsökende evne
GB0102145D0 (en) Substances
PT1435991E (pt) Utilização de aplidina para o tratamento de cancro pancreático
WO1997026918A3 (en) Ligand directed enzyme prodrug therapy
ATE407702T1 (de) Liposomale einkapselung von alphastrahlern, und deren verwendung
PT1406859E (pt) Derivados substituídos de 4-aminociclo-hexanol
WO2002066492A3 (fr) Anticorps specifique de l'adrenomedulline humaine, composition pharmaceutique le contenant, ses applications therapeutiques.
PT980379E (pt) Oligonucleotidos quimericos e sua utilizacao
UA34406A (uk) Засіб для лікування розсіяного склерозу, спосіб лікування з його використанням та фармацевтична упаковка
MXPA04003673A (es) Uso de aplidina para el tratamiento de cancer pancreatico.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application